BioCryst launch­es aware­ness cam­paign around man­age­ment of rare vas­cu­lar dis­ease

While hered­i­tary an­gioede­ma (HAE) is rare, treat­ment op­tions for the con­di­tion have be­come much more com­mon. So BioCryst Phar­ma­ceu­ti­cals is tak­ing a new an­gle in its re­cent­ly launched HAE aware­ness cam­paign en­cour­ag­ing pa­tients to take con­trol of their dis­ease man­age­ment.

“Hered­i­tary an­gioede­ma (HAE) isn’t the au­thor of your sto­ry — you are … #cHAEngeth­e­p­lan. Not the goal,” the US cam­paign web­site ad­vis­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER